Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?
July 27, 2011 updated by: Sorlandet Hospital HF
Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder, a Prospective, Randomized Pilot Study With Wait List as Control Group.
The purpose of this study is to find out if Thought Field Therapy has effect on certain anxiety disorders; agoraphobia, social phobia, and post traumatic stress disorder (PTSD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Thought Field Therapy is an alternative treatment method that has been shown, by casuistic reports, to give good results when applied for anxiety disorders.
In this study 52 patients, with one or more of the diagnoses agoraphobia, social phobia and/or PTSD, where randomized to either treatment with TFT or a wait list.
The treatment group all got treatment in one week.
2 1/2 months later both the treatment group and the control group were tested on the same items as before the treatment started.
After this evaluation phase the control group got the same treatment as the treatment or study group.
Both groups were evaluated 3 and 12 months after treatment, the study group also 6 months after treatment.
4 patients were omitted because they changed groups.
The study were performed from May 2002 until June 2003.
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Arendal, Norway, 4809
- Sorlandet hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- One or more of the study diagnoses agoraphobia, social phobia and/or PTSD
Exclusion Criteria:
- Ongoing psychosis
- Ongoing serious drug problems
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Thought Field Therapy (TFT)
Treatment with TFT, first one hour, then 1/2 hour.
|
Treatment with TFT twice in one week
Other Names:
|
|
No Intervention: Wait list control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Global symptom index (gsi) on the Symptom checklist 90 revised (SCL-90-R)
Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Davidson Trauma Scale
Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
|
Liebowitz Social Anxiety Scale
Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
|
Fear Questionnaire (FQ)
Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
|
Sheehan Disability Scale
Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Audun C Irgens, MD, Sorlandet Hospital HF
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2002
Primary Completion (Actual)
August 1, 2003
Study Completion (Actual)
August 1, 2003
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 20, 2005
Study Record Updates
Last Update Posted (Estimate)
July 28, 2011
Last Update Submitted That Met QC Criteria
July 27, 2011
Last Verified
September 1, 2005
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SSHF-AUIR-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.